Pezadeftide in Action

How is Pezadeftide better than other treatments?

Pezadeftide penetrates the nail more effectively than existing topical treatments and so can more readily target the fungal cells which proliferate in the nail bed. It is also more effective at rapidly killing fungal cells on contact. Together, these properties mean that pezadeftide has the potential to resolve the fungal infection more quickly, leading to faster and more complete clearing of the infected nail area. Consequently, pezadeftide offers the promise to capture significant value in a large and poorly served market.

In a phase 1/2a dose-escalation study of pezadeftide applied topically to patients with mild to moderate onychomycosis pezadeftide was safe and well-tolerated and substantially reduced the area of infection with a much shorter treatment period than current best-in-class therapies.

Following 6 weeks of daily application, pezadeftide’s Mycological Cure* rate measured 12 weeks after the start of treatment was ~2-fold higher than current treatments at the same time point.

Images from HXP124-ONY-001 clinical trial

* Mycological Cure = no fungus in samples collected from underneath the nail as assessed by stain (microscopy) and culture (growth).

References

1.Tatchibana et al., Journal of Fungi, 2017; 2.Persistence Market Research 2018; 3.ClearView Healthcare Partners proprietary market research, 2019; 4.Joseph et al, Supplement to Podiatry Today, 2013; 5. Milobratovic et al., Mycoses, 2013; 6. Internal Hexima research; 7. Kaken Pharma and Dow Pharma, Sugiura et al., 2014; 8. UCSF Medical Center, Hui et al., 2006; 9. HXP124 PI/IIa clinical trial, HXP124-ONY-001 (ACTRN12618000131257); 10. Efinaconazole FDA and PMDA reviews; 11. Evans & Sigurgeirsso, BMJ, 1999;